Evidence map›Paper›PMID 36301485›Full record

ArticleDermatology and therapy2022

Predicting Clinical Remission of Chronic Urticaria Using Random Survival Forests: Machine Learning Applied to Real-World Data.

Irina Pivneva, Maria-Magdalena Balp, Yvonne Geissbühler, Thomas Severin, Serge Smeets, James Signorovitch, Jimmy Royer, Yawen Liang, Tom Cornwall, Jutong Pan and 4 more

Open access · goldAbstract read
In one paragraph

Article in Dermatology and therapy, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
2.2field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 13 citations in OpenAlex.

  1. Review
  2. Exploring the Disease Duration of Urticaria and Associated Determinants in Primary Care.Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology · 2026
    Article
  3. Preparing Allergists to Practice in 2050 Using Artificial Intelligence.The journal of allergy and clinical immunology. In practice · 2025
    Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 6 institutions in 5 countries.

Irina PivnevaAnalysis Group, Inc., 1190 Avenue des Canadiens-de-Montréal, Tour Deloitte, Suite 1500, Montréal, QC, H3B 0G7, Canada. irina.pivneva@analysisgroup.com.
Maria-Magdalena BalpNovartis Pharma AG, Basel, Switzerland.
Yvonne GeissbühlerNovartis Pharma AG, Basel, Switzerland.
Thomas SeverinNovartis Pharma AG, Basel, Switzerland.
Serge SmeetsNovartis Pharma AG, Basel, Switzerland.
James SignorovitchAnalysis Group, Inc., Boston, MA, USA.
Jimmy RoyerAnalysis Group, Inc., 1190 Avenue des Canadiens-de-Montréal, Tour Deloitte, Suite 1500, Montréal, QC, H3B 0G7, Canada.
Yawen LiangAnalysis Group, Inc., 1190 Avenue des Canadiens-de-Montréal, Tour Deloitte, Suite 1500, Montréal, QC, H3B 0G7, Canada.
Tom CornwallAnalysis Group, Inc., 1190 Avenue des Canadiens-de-Montréal, Tour Deloitte, Suite 1500, Montréal, QC, H3B 0G7, Canada.
Jutong PanAnalysis Group, Inc., 1190 Avenue des Canadiens-de-Montréal, Tour Deloitte, Suite 1500, Montréal, QC, H3B 0G7, Canada.
Andrii DanylivNovartis Pharma AG, Basel, Switzerland.
Sarah Jane McKennaNovartis Business Services, Dublin, Ireland.
Alexander M Marsland *Salford Royal NHS Foundation Trust and University of Manchester, Salford, UK.
Weily Soong *AllerVie Health and AllerVie Clinical Research, Birmingham, AL, USA.
Group for Research in Decision Analysis · CANovartis (Switzerland) · CHAbbVie (United States) · USAnalysis Group (United States) · USNovartis (Ireland) · IESalford Royal NHS Foundation Trust · GB

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionThe time required to reach clinical remission varies in patients with chronic urticaria (CU). The objective of this study is to develop a predictive model using a machine learning methodology to predict time to clinical remission for patients with CU.

methodsAdults with ≥ 2 ICD-9/10 relevant CU diagnosis codes/CU-related treatment > 6 weeks apart were identified in the Optum deidentified electronic health record dataset (January 2007 to June 2019). Clinical remission was defined as ≥ 12 months without CU diagnosis/CU-related treatment. A random survival forest was used to predict time from diagnosis to clinical remission for each patient based on clinical and demographic features available at diagnosis. Model performance was assessed using concordance, which indicates the degree of agreement between observed and predicted time to remission. To characterize clinically relevant groups, features were summarized among cohorts that were defined based on quartiles of predicted time to remission.

resultsAmong 112,443 patients, 73.5% reached clinical remission, with a median of 336 days from diagnosis. From 1876 initial features, 176 were retained in the final model, which predicted a median of 318 days to remission. The model showed good performance with a concordance of 0.62. Patients with predicted longer time to remission tended to be older with delayed CU diagnosis, and have more comorbidities, more laboratory tests, higher body mass index, and polypharmacy during the 12-month period before the first CU diagnosis.

conclusionsApplying machine learning to real-world data enabled accurate prediction of time to clinical remission and identified multiple relevant demographic and clinical variables with predictive value. Ongoing work aims to further validate and integrate these findings into clinical applications for CU management.

Indexed as

Chronic urticariaElectronic health recordsMachine learningPredictorsRandom survival forestRemissionTime to clinical remission

Identifiers

PMID36301485
PMCPMC9674814
OpenAlexW4307429571

What Socratic holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.